Viking Therapeutics Set to Engage Investors at Upcoming Conferences
Viking Therapeutics Set to Engage Investors at Upcoming Conferences
Viking Therapeutics, Inc., a biopharmaceutical company actively progressing in the realm of novel therapies for metabolic and endocrine disorders, has announced its participation in two significant investor events this June. As the company continues to pave the way for innovative treatments, these conferences offer a prime opportunity to engage with investors and communicate its strategic vision for future growth.
Upcoming Conferences
Viking Therapeutics will participate at the William Blair 46th Annual Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York. The details of each event are as follows:
1. William Blair 46th Annual Growth Stock Conference
- - Dates: June 2-4, 2026
- - Presentation by Management: June 2nd, 2:00 PM - 2:30 PM CT
- - Breakout Session: June 2nd, 2:40 PM - 3:10 PM CT
- - Location: Chicago, IL
During this conference, the management team from Viking will deliver a corporate presentation, which will be followed by a breakout session to dive deeper into potential investor queries and foster productive discussions. This conference serves as an important platform for establishing connections with potential investors and sharing insights into the company’s pipeline.
2. Jefferies Global Healthcare Conference
- - Dates: June 3-4, 2026
- - Fireside Chat: June 4th, 1:25 PM - 1:55 PM ET
- - Location: New York, NY
At the Jefferies event, Viking's team will partake in a fireside chat which aims to provide an engaging format for discussing the company’s advancements and answering inquiries from attendees. A live webcast of the discussion will be accessible via the Viking Therapeutics website, ensuring that remote investors can also partake in the dialogue and gain valuable insights into the company's activities.
Viking’s Focus on Innovative Therapeutics
Viking Therapeutics has made notable strides in developing first-in-class therapies aimed at treating metabolic and endocrine disorders. The company is especially focused on its lead program, VK2735, which acts as a dual agonist for glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This innovative approach could hold significant promise for various metabolic disorders.
Furthermore, Viking's pipeline includes additional formulations, such as an oral version of VK2735, currently under evaluation in a Phase 2 trial for obesity. Recent data from prior trials demonstrate a positive safety profile as well as a good tolerability rate, alongside academic observations of notable clinical benefits.
In addition to VK2735, Viking is advancing VK2809, designed for treating lipid and metabolic disorders, as well as VK0214, aimed at addressing rare diseases such as X-linked adrenoleukodystrophy (X-ALD).
The commitment to rigorous research and development illustrates Viking’s dedication to enhancing patient outcomes through innovative therapeutic solutions.
For continuous updates about Viking Therapeutics and insights from the upcoming conferences, you can visit their investor relations section on Viking's official website. This showcase of their upcoming events is a promising step toward fostering more profound connections within the investment community while also signalling their commitment to advancing health science.
In conclusion, Viking Therapeutics is set to make a significant impression this June as it participates in vital investor discourse, shedding light on the promising future of its therapeutic endeavors while aiming to address unmet medical needs in the metabolic disorder domain.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.